



A Metagenomic Analysis Provides a Culture-Independent Pathogen Detection for Atopic Dermatitis

Min-Hye Kim,¹ Mina Rho,² Jun-Pyo Choi,³ Hyun-Il Choi,⁴ Han-Ki Park,⁵ Woo-Jung Song,⁶ Taek-Ki Min,⁷ Sang-Heon Cho,⁶ Young-Joo Cho,¹ Yoon-Keun Kim,⁸ Sanghwa Yang,^{8*} Bok Yang Pyun^{7*}

¹Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea

²Department of Computer Science and Engineering, Hanyang University, Seoul, Korea

³Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

⁴Division of Molecular and Life Sciences, Department of Life Science, Pohang University of Science and Technology, Pohang, Korea

⁵Department of Allergy and Clinical Immunology, Ajou University Medical Center, Suwon, Korea

⁶Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

⁷Department of Pediatrics, Pediatric Allergy and Respiratory Center, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea

⁸Institute of MD Healthcare, Seoul, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose: Atopic dermatitis (AD) is an inflammatory skin disease, significantly affecting the quality of life. Using AD as a model system, we tested a successive identification of AD-associated microbes, followed by a culture-independent serum detection of the identified microbe. **Methods:** A total of 43 genomic DNA preparations from washing fluid of the cubital fossa of 6 healthy controls, skin lesions of 27 AD patients, 10 of which later received treatment (post-treatment), were subjected to high-throughput pyrosequencing on a Roche 454 GS-FLX platform. **Results:** Microbial diversity was decreased in AD, and was restored following treatment. AD was characterized by the domination of *Staphylococcus*, *Pseudomonas*, and *Streptococcus*, whereas *Alcaligenaceae* (f), *Sediminibacterium*, and *Lactococcus* were characteristic of healthy skin. An enzyme-linked immunosorbent assay (ELISA) showed that serum could be used as a source for the detection of *Staphylococcus aureus* extracellular vesicles (EVs). *S. aureus* EV-specific immunoglobulin G (IgG) and immunoglobulin E (IgE) were quantified in the serum. **Conclusions:** A metagenomic analysis together with a serum detection of pathogen-specific EVs provides a model for successive identification and diagnosis of pathogens of AD.

Key Words: Atopic dermatitis; extracellular vesicle; metagenomic analysis

INTRODUCTION

Atopic dermatitis (AD) is a recurrent, chronic inflammatory skin disease which is characterized by itching and xerosis, and is closely associated with immunoglobulin E (IgE)-mediated sensitization to allergens.^{1,2} Skin barrier dysfunction, allergic or microbial skin colonization, and decreased innate immune responses are considered significant causes for AD.^{3,4} The prevalence of AD is increasing in developed countries, with incidence rates reaching up to 30% in children and up to 10% in adults.⁵⁻⁷ The skin microbiome has also been implicated in the pathogenesis of AD. For example, a localized pathogen and a constituent of general skin microbiota, *Staphylococcus aureus* (*S. aureus*) were shown to be involved in the local skin inflammation,^{1,8,9} and its exotoxin acted as a superantigen that induced T-cell and IgE responses.^{1,10,11} The lack of studies concerning the skin mi-

crobiome has precluded a deep understanding of the effect of skin bacteria.

Traditional 16S ribosomal RNA (rRNA) gene sequence analysis has recently expanded into a metagenomic analysis, where a massively parallel high-throughput next-generation DNA se-

Correspondence to: Bok Yang Pyun, MD, Department of Pediatrics, Pediatric Allergy and Respiratory Center, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, 59 Daesagwan-ro, Yongsan-gu, Seoul 04401, Korea.

Tel: +82-2-709-9339; Fax: +82-2-794-5471; E-mail: bypyun@schmc.ac.kr

Co-Correspondence to: Sanghwa Yang, PhD, Institute of MD Healthcare, 9 World Cup buk-ro 56-gil, Mapo-gu, Seoul 03923, Korea.

Tel: +82-2-7812-8061; Fax: +82-2-2655-0768; E-mail: arraychip@gmail.com
Received: November 14, 2016; Revised: March 27, 2017; Accepted: April 4, 2017

• Min-Hye Kim and Mina Rho contributed equally to this paper.

• There are no financial or other issues that might lead to conflict of interest.

quencing of variable (V) regions of bacterial gene coding for 16S rRNA, a 16S metagenomic sequencing, can potentially identify and classify an unprecedented number of skin microbiota in a culture-independent manner.¹² The introduction of metagenomics also provided key information about the types of microbes and the composition of microbiota on normal healthy skin. For example, whereas healthy saliva shows high alpha diversity and low beta diversity, the antecubital fossa region of the skin has high beta diversity and intermediate level of alpha diversity, implicating that the microbiome composition of normal subjects' skin shows one of the highest level of variations among individuals.¹³

The microbiome study regarding AD has always been of great interest, since a large portion of child population is susceptible to this disease caused by physical pain and emotional stress. Of the cultivatable microorganisms, *S. aureus* has been consistently reported to be associated with AD, including a report that confirmed that severe AD showed a positive correlation with reduced skin bacterial diversity and that *Staphylococcus* was the most dominant bacterium found in the antecubital crease, contributing to the reduction of microbial diversity in AD and to the positive partial correlation to disease severity.¹⁰

Extracellular vesicles (EVs) are nanometer-sized membrane vesicles derived from prokaryotes, archaea, and eukaryotes, and function not only intercellular signaling mediators using enclosed proteins, nucleic acids, and lipids but also as a source of novel biomarkers in the diagnosis and prognosis of disease.^{14,15} Most importantly, EVs can be purified from body fluids, including plasma and urine, thereby providing an excellent tool to probe the effect of bacterial infection on a systemic level.¹⁶ We also previously reported that *S. aureus*-derived EVs induced AD-like inflammation in the skin and were causally related to the pathogenesis of AD.^{17,18}

Here, we analyzed the bacterial communities in skin washing fluid from AD patients and normal controls by 16S metagenomic sequencing to define the microbial composition contributing to AD and to evaluate its changes following eczema treatment. Furthermore, we tested systemic bacterial presence through detecting *S. aureus*-derived EVs in AD patients using an enzyme-linked immunosorbent assay (ELISA)-based method to probe the relationship between the presence of *S. aureus* in the skin and the EV-specific immunoglobulin G (IgG) in the serum of AD patients.

MATERIALS AND METHODS

Study population

This study was approved by the ethics committee of Soonchunhyang University Hospital (approval number 2013-061) and was composed of 6 normal controls and 27 AD patients. Of the 27 AD patients, 10 were provided with skin washing fluid before and after AD treatment. Therefore, total of 43 metagenomic se-

quencing data were generated from 33 study subjects. Patients with aggravated AD according to the Hanifin and Rajka AD diagnostic criteria¹⁹ were enrolled at the Pediatric Allergy and Respiratory Center of Soonchunhyang University Hospital. Informed consent forms were obtained from the participants and their parents. Patients who had other skin diseases or had received topical/oral/injectable antibiotics within the previous 14 days were excluded. Normal control subjects consisted of children who had no previous skin diseases, including AD, or any other allergic or significant underlying diseases, and had no medication history. AD treatment included wet dressing and treatment with topical corticosteroids, antihistamines, and antibiotics.

Collection of skin washing fluid

Saline-soaked gauzes were placed on the skin lesions, mainly the cubital fossae of AD patients, before and after treatment for 10-15 minutes. The retrieved gauzes were stored in containers filled with saline solution. For the control group, saline-soaked gauzes were placed on the cubital fossa and were processed in the same way.

Laboratory tests and measurement of AD severity

White blood cells, eosinophil count, total IgE, and eosinophil cationic protein (ECP) were measured in AD patients. Laboratory tests were not performed in normal controls. AD severity was measured by the SCORing Atopic Dermatitis (SCORAD) index.²⁰

DNA isolation and emulsion-based polymerase chain reaction (emPCR)

Bacterial DNAs were purified from skin washing fluid using PowerWater[®] DNA Isolation Kit (MO BIO Laboratories, Carlsbad, CA, USA). Libraries were prepared according to the Rapid Library Preparation Method Manual for GS FLX plus series (Roche, Branford, CT, USA). Libraries were quantified using Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). The emPCR, corresponding to clonal amplifications of the purified libraries, was carried out using the GS-FLX plus emPCR Kit (Roche). Briefly, libraries were immobilized onto DNA capture beads, added to a mixture of amplification mix and oil, and were vigorously shaken on a TissueLyser II (Qiagen, Valencia, CA, USA) to create "micro-reactors" containing both amplification mix and a single bead. Emulsion was dispensed into a 96-well plate and the PCR amplification program was run according to the manufacturer's recommendation. Then, 20 ng aliquot of each sample DNA was used for a 50 μ L PCR reaction. Universal primers 27F (5'-GAGTTTGATCMTGGCTCAG-3'), 518R (5'-WTTACCGCGCTGCTGG-3') were used for the amplification of variable regions 1 through 3 (V1-V3) of bacterial 16S rRNA genes. The FastStart[™] High Fidelity PCR System (Roche) was used for the following PCR conditions: 94°C for 3 minutes followed by 35 cycles of 94°C for 15 seconds,

55°C for 45 seconds, and 72°C for 1 minute, followed by a final elongation step at 72°C for 8 minutes. The PCR products were purified using Agencourt AMPure XP system (Beckman Coulter Inc., Brea, CA, USA).

Next generation sequencing (NGS)

Sequencing was performed on a Genome Sequencer FLX plus System (Roche) at Macrogen (Seoul, Korea). Following PCR amplification, the emulsion was chemically broken, and the beads carrying the amplified DNA libraries were recovered and washed by filtration. Positive beads were purified using the biotinylated primer A (complementary to adaptor A), which binds to streptavidin-coated magnetic beads. The DNA library beads were separated from the magnetic beads by melting the double-stranded amplification products. The sequencing primer was then annealed to the amplified single-stranded DNA. Finally, beads carrying amplified single-stranded DNA were counted with a Particle Counter (Beckman Coulter Inc.). Each sample was loaded in 1 region of a 70-75 mm PicoTiter plate (Roche) fitted with an 8-lane gasket.

Analysis of NGS data

Analysis and interpretation of NGS data were carried out at MD Healthcare (Seoul, Korea). The high-quality sequencing reads were selected after checking the read length (≥ 300 bp) and the quality score (average Phred score ≥ 20). Operational Taxonomy Units (OTUs) were clustered by using sequence clustering algorithms UCLUST.²¹ Subsequently, taxonomy assignment against the 16sRNA sequence database in GreenGenes 8.15.13 was carried out by using QIIME.²² Based on the sequence similarities, all 16sRNA sequences were assigned to the following taxonomic levels: species (s), $\geq 97\%$ similarity; genus (g), $\geq 94\%$ similarity; family (f), $\geq 90\%$ similarity; order (o), $\geq 85\%$ similarity; class (c), $\geq 80\%$ similarity; and phylum (p), $\geq 75\%$ similarity. The bacterial composition at the genus level was plotted in the heatmap if a genus cluster shows significantly different composition between 2 groups (≥ 2 -fold change in composition between the AD and control groups). In case clusters could not be assigned at the genus level due to the lack of sequences or redundant sequences in the database, the taxon was assigned at the higher level, which is indicated in the parenthesis.

Evaluation of *S. aureus* exotoxin B-specific/*S. aureus*-derived EV-specific IgG and IgE

For the measurement of specific IgG and IgE levels, 1.25 μg of *S. aureus* exotoxin B and 100 ng of *S. aureus* EV were coated on a polystyrene plate (Corning Inc., Corning, NY, USA), respectively. After overnight incubation, bovine serum albumin (1% weight per volume in phosphate-buffered saline [PBS]) was used to block non-specific bindings for 1 hour at room temperature prior to the addition of a 1:1,000 dilution of serum. Horseradish peroxidase-conjugated secondary antibody was added and in-

cubated for 1 hour, and the absorbance was measured in a VersaMax™ ELISA Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). IgG and IgE levels were measured using human IgG and IgE ELISA kits (Bethyl Laboratories, Montgomery, TX, USA for each), according to the manufacturer's instructions.

RESULTS

Clinical characteristics of AD patients and normal controls

Thirty-three subjects were enrolled, including 27 AD patients and 6 normal controls. The mean age of the AD patients and controls was 91 and 83 months, respectively. Eighteen AD patients and 4 normal controls were male (both 66.7%). Mean eosinophil count and ECP level were 877 per μL and 66.4 $\mu\text{g}/\mu\text{L}$, respectively, in the peripheral blood of patients. Of the 26 AD patients who were positive for IgE response to allergens, 17 were IgE-positive specifically for house dust mites. Mean SCORAD index was significantly decreased from 72.5 ± 19.9 before treatment to 41.4 ± 16.2 after treatment ($P < 0.001$) among patients, implicating the effectiveness of used treatment (Table 1). Microbial 16S rRNA gene (V1-V3 regions)-based metagenomic sequencing was performed on 6 controls and 27 patients, of which 10 were further subjected to metagenome analysis following AD treatment (materials and methods).

Bacterial composition in skin washing fluid

A total of 18 bacterial genera showed differential compositions (≥ 2 -fold change) between AD patients and normal controls from a metagenomic analysis of skin washing fluid (Fig. 1). In AD patients, *Staphylococcus* accounted for the highest proportion of microorganisms at 66.2%, followed by *Pseudomonas* (11.6%), *Streptococcus* (6.19%), and *Acinetobacter* (1.21%). Each

Table 1. Clinical characteristics of the AD patients and normal controls

Characteristics	AD
Number	27
Age (mon)	91.4 \pm 64.0
Male gender (%)	18 (66.7)
White blood cells (/ μL)	11,059.3 \pm 4,903.9
Blood eosinophil count (/ μL)	877.8 \pm 751.6
CRP (mg/dL)	0.16 \pm 0.34
Total IgE (KU/L)	2,810.0 \pm 4,408.1
ECP ($\mu\text{g}/\text{L}$)	66.4 \pm 59.4
Specific IgE(+) to HDM (Df or Dp)	18 (66.7)
Specific IgE(+) to any allergen	26 (96.3)
SCORAD index before treatment	72.5 \pm 19.9
SCORAD index after treatment	41.4 \pm 16.2

Values are presented as mean \pm SD or number (%).

AD, atopic dermatitis; CRP, C-reactive protein; ECP, eosinophil cationic protein; HDM, house dust mite; Df, *Dermatophagoides farinae*; Dp, *Dermatophagoides pteronyssinus*; SCORAD, SCORing of Atopic Dermatitis; SD, standard deviation.

of the genera *Lactobacillus*, *Xanthomonadaceae* (f), *Leuconostoc*, *Alcaligenaceae* (f), *Lactococcus*, *Rhizobiales* (o), and *Methylobacterium* accounted for more than 1% of microbial compo-

sitions. On the other hand, the most dominant microorganism in the skin of normal controls was *Alcaligenaceae* (f) at 40.4%, which was a drastic increase from 0.03% in AD patients. The




Fig. 1. Comparison of bacterial composition in the skin washing fluid of AD patients (case) and normal controls. (A, B) In the skin washing fluid of patients, *Staphylococcus* accounted for the majority of bacteria, followed by *Pseudomonas* and *Streptococcus* in the heatmap. In normal controls, *Staphylococcus*, *Pseudomonas*, and *Streptococcus* were hardly detected, whereas *Sediminibacterium*, *Alcaligenaceae* (f) were predominant. AD, atopic dermatitis; f, family.




Fig. 2. Changes in the bacterial proportion of skin washing fluid in patients with AD before and after treatment. (A, B) The proportion of *Staphylococcus* decreased after treatment. Increasing proportions following treatment were evident for *Alicyclobacillus*, *Propionibacterium*, and *Streptococcus*. AD, atopic dermatitis.

next highest proportions of normal microbiota were *Sediminibacterium* (13.2%) and *Lactococcus* (3.9%), whose proportions were drastically decreased to 0% and 0.3%, respectively in AD patients. Overall, for the bacterial genera that showed differential compositions between the 2 groups, normal skin washing fluid showed 18 bacterial types with varying compositions from 0.22% for *Staphylococcus* (f) to 40.36% for *Alcaligenaceae* (f), whereas skin washing fluids from AD patients showed only 11 detectable microbial compositions, showing greatly decreased microbial diversity.

Staphylococcaceae, *Pseudomonadaceae* and *Streptococcaceae*

(f), *Bacillales* and *Pseudomonadales* (o), *Bacilli* (c), and *Firmicutes* (p) were the dominant microorganisms in AD patients. On the contrary, *Alcaligenaceae* (f), *Burkholderiales* (o), *Betaproteobacteria* (c), and *Proteobacteria* (p) composed the major bacteria in the washing fluid of normal controls (Supplementary Fig. 1). At the genus level, the major composition of *Staphylococcus* was followed by *Pseudomonas* and *Streptococcus* in AD patients, whereas *Alcaligenaceae* and *Sediminibacterium* were more frequent in controls (Supplementary Fig. 2).

Further analysis confirmed the major *Staphylococcus* species as *S. aureus*, in AD patients, with relatively minor prevalence of




Fig. 3. Bacterial community analysis of skin washing fluid of AD patients with before and after treatment according to the phylogenetic hierarchy of phylum, class, order, and family. (A) In AD patients, *Firmicutes* was dominant before treatment and decreased following treatment, with *Actinobacteria* being increased after treatment. (B) *Bacilli* dominated before treatment and decreased after treatment, with *Actinobacteria* being increased after treatment at the class level. (C) *Bacillales* were dominant before treatment and decreased after treatment, with *Propionibacteriales* and *Lactobacillales* being increased after treatment at the order level. (D) *Staphylococcaceae* was dominant before treatment and was decreased after treatment, with *Alicyclobacillaceae*, *Propionibacteriaceae* and *Streptococcaceae* increased after treatment at the family level. AD, atopic dermatitis.

S. haemolyticus and *S. epidermidis* (Supplementary Fig. 3).

Changes in bacterial composition and diversity following AD treatment

Treatment of AD patients with wet dressing or other anti-inflammatory drugs (materials and methods) brought into alleviation of symptoms together with changes in bacterial compositions. The proportion of *Staphylococcus* significantly decreased from 38.8% to 5.7% of the total microbiota following treatment. At the same time, increasing proportions were observed for *Alicyclobacillus* (2.21% to 6.03%), *Propionibacterium* (2.24% to 4.62%), and *Streptococcus* (0.47% to 6.47%, Fig. 2). At a phylum level, *Firmicutes* and *Actinobacteria* showed opposite pattern in composition, with *Firmicutes* being decreased and *Actinobacteria* showing increase in composition following treatment (Fig. 3). Microorganisms that belonged to the class of *Bacilli* (c),

Bacillales (o) and *Staphylococcaceae* (f) dominated before treatment and decreased after treatment, whereas *Propionibacteriales* (o), *Lactobacillales* (o), *Alicyclobacillaceae*, *Propionibacteriaceae*, and *Streptococcaceae* (f) increased after treatment. At the genus level, *Staphylococcus* was reduced, while *Alicyclobacillus*, *Propionibacterium*, and *Streptococcus* were increased, and bacterial diversity was restored after treatment compared to before treatment (Fig. 4).

Previous results showed that AD patients had lower microbial diversity as measured by the Shannon-Weiner index and also by Simpson index.²¹ We tested if changes in microbial diversity can be observed among normal subjects, AD patients, and patients who received eczema treatment (Table 2). The Shannon index was significantly lower in AD patients (2.4 ± 1.6) than in normal controls (4.8 ± 1.2). A subpopulation of patients who received treatment showed recovery in microbiota diversity as




Fig. 4. Bacterial community analysis of skin washing fluid of AD patients with before and after treatment in the genus level. (A, B) *Staphylococcus* was reduced, while *Alicyclobacillus*, *Propionibacterium*, and *Streptococcus* were increased and bacterial diversity was restored after treatment compared to that before treatment. AD, atopic dermatitis.

shown with an increase in the Shannon index from 3.2 ± 1.2 to 5.4 ± 1.7 (Table 3).

Quantitation of serum IgG and IgE against exotoxin B and EVs from *S. aureus*

We previously showed that there was a causal relationship between *S. aureus*-derived EV and the pathogenesis of AD,¹⁷ and there was also a report showing that *S. aureus* was the major bacterium found in the skin of AD patients.⁹ Therefore, we tested if the *S. aureus*-derived EVs could be detected in the serum through measuring EV-specific IgE in the serum, also using *S. aureus* exotoxin B as a positive experimental control.

The levels of exotoxin-specific IgG and IgE were significantly higher in AD patients: 65.9 ± 66.0 $\mu\text{g/mL}$ for IgG and 1.2 ± 0.3

$\mu\text{g/mL}$ for IgE in controls and 220.8 ± 188.5 $\mu\text{g/mL}$ for IgG and 3.4 ± 4.6 $\mu\text{g/mL}$ for IgE in AD patients ($P=0.008$ and $P=0.047$, respectively). EV-specific IgG and IgE levels were also significantly higher in AD patients: 21.7 ± 48.4 $\mu\text{g/mL}$ for IgG and 3.1 ± 0.5 $\mu\text{g/mL}$ for IgE in controls and 144.4 ± 93.3 $\mu\text{g/mL}$ for IgG and 6.9 ± 3.9 $\mu\text{g/mL}$ for IgE in AD patients ($P=0.001$) (Fig. 5). These results confirm that serum can be used to detect the presence of *S. aureus*, the most dominant microorganism associated with AD.

DISCUSSION

Microorganisms contribute to diverse human pathogenesises, not by their presence, but by their imbalance in the composition

Table 2. Microbial diversities in AD patients and normal controls

Variables	Normal control	AD (pre-treatment)	Pvalue
# OTUs	419.00 \pm 107.81	330.33 \pm 156.11	0.202
Richness (Chao1)	1,252.37 \pm 231.11	1,033.11 \pm 375.22	0.185
Shannon index	4.75 \pm 1.15	2.44 \pm 1.61	0.003

Values are presented as mean \pm SD, 5,000 reads.

AD, atopic dermatitis; OTUs, Operational Taxonomy Units; SD, standard deviation.

Table 3. Microbial diversity test in AD patients following treatments

Variables	Pre-treatment (n=8)	Post-treatment (n=8)	Pvalue
# OTUs	357.38 \pm 119.88	376.63 \pm 104.21	0.674
Richness (Chao1)	1,092.61 \pm 239.36	1,126.31 \pm 215.34	0.889
Shannon index	3.18 \pm 1.34	5.41 \pm 1.65	0.036

Values are presented as mean \pm SD, 5,000 reads.

AD, atopic dermatitis; OTUs, Operational Taxonomy Units; SD, standard deviation.




Fig. 5. SEB-specific IgG and IgE and *S. aureus* EV-specific IgG and IgE levels. (A, B) SEB-specific IgG and IgE levels were significantly higher in the serum of AD patients compared with that of normal controls. (C, D) *S. aureus* EV-specific IgG and IgE levels were significantly higher in the serum of AD patients compared with those of normal controls. SEB, *S. aureus* exotoxin B; IgG, immunoglobulin G; IgE, immunoglobulin E; EV, extracellular vesicle; AD, atopic dermatitis.

of microbiota. In contrast to the conventional culture-based assays, metagenome analysis makes it possible to identify and count relative abundance of all species present.¹² In this report, we compared the bacterial compositions between normal subjects and AD patients, and also between pre- and post-treatment groups of AD patients.

The most dominant microorganisms in the skin of normal control were *Alcaligenaceae* (f) (40.4%), followed by *Sediminibacterium* (13.2%) and *Lactococcus* (3.9%). However, in AD patients, the proportion of *Alcaligenaceae* (f) was drastically reduced to 0.03% and *Lactococcus* and *Sediminibacterium* were also reduced to less than 1%. On the contrary, we showed that *Staphylococcus* became the most dominant bacteria in AD patients at 66.2%, which was in accordance with the results of a previous report.⁵ Higher compositions of other bacteria in AD patients, including *Pseudomonas* (11.6%) and *Streptococcus* (6.19%) were also observed. Therefore, 2 different microbial signatures represented the 2 states of normal controls and AD patients. Drago et al.²³ also reported that *Firmicutes* and *Staphylococcaceae* were the most abundant phylum and family, respectively, and *S. aureus* accounted 73% of total staphylococci load in the skin of AD patients. However, unlike our study, they failed to show the different microbial composition between AD patients and normal controls except higher frequency of *S. aureus*. Seite et al.²⁴ also revealed that *Staphylococcus*, *Propionibacterium*, and *Streptococcus* were abundant in the lesional skin of AD patients. In contrast, *S. epidermidis* was the most common among the *Staphylococcus* species.

The increased prevalence of *Streptococcus*, *Propionibacterium*, and *Corynebacterium* after AD treatment was reported earlier.¹⁰ In our study, *Alicyclobacillus*, *Propionibacterium*, and *Streptococcus* were increased after treatment.

Changes in microbial compositions between normal controls and AD patients were also illustrated by decreased microbial diversity. Recovery of the bacterial diversity after AD treatment was also observed. In this case, *Alicyclobacillus* (from 2.21% to 6.03% post-treatment), *Propionibacterium* (2.24% to 4.62%), and *Streptococcus* (0.47% to 6.47%) were all increased after AD treatment, which was also in line with the result of a previous report,¹⁰ where the increases in the microbial compositions of *Streptococcus*, *Propionibacterium*, and *Corynebacterium* after eczema treatment were documented. However, the bacterial composition of patients following treatment was not identical with that of normal controls, implying that the AD treatment causes increased diversity, but the treatment does not necessarily restore the microbial composition to the original state of normal controls. AD patients are vulnerable to *S. aureus* infection and colonization. *S. aureus* colonization occurs in 90% of AD patients but in only 10% of normal subjects.^{1,9} In the current study, we showed that *Staphylococcus* was dominant in skin washing fluid from AD patients compared with normal controls. In AD patients, the dominance of *Staphylococcus* was sig-

nificantly reduced following treatment, contributing to the greater microbial diversity. This may suggest that the decreased microbial diversity due to the dominance of *Staphylococcus* is one of the major factors that represent AD. Even though it is not known whether the increase in *Propionibacterium* and *Corynebacterium* is the result of the decrease in *Staphylococcus* and vice versa, the combined decrease in *S. aureus* and increases in *Streptococcus*, *Propionibacterium*, and *Corynebacterium* might be utilized as an indicator of recovery from deterioration of AD.

Bacterial membrane vesicles with active biomolecules are extracellularly released into human biofluids and can function as carriers of signaling molecules between microorganisms and host cells or among themselves.²⁵ These EVs also provide excellent sources for a non-invasive diagnosis of diseases associated with the presence of microorganisms, since they are readily recovered from blood, urine, and other biofluids.²⁶ Previous results revealed that *S. aureus*-derived EVs induced skin barrier disruption and cause AD-like skin inflammation.¹⁷ This is consistent with an ELISA performed in this study, in which EV-specific IgG and IgE increased 2-fold in AD patients compared with normal controls. We showed compositional changes in patients with AD and its treatment by high throughput 16S rRNA metagenomic analysis and also showed that the most dominant *S. aureus* in AD can be detected by the presence of its EV in patients' serum.

Since EVs are produced from all forms of life and present in diverse body fluids, such as plasma, serum, saliva, urine, breast milk, and ascites,²⁷ the combined approach of metagenomic sequencing analyses of patients' body fluids and EV-based microbe detection provide a novel approach for a quick and efficient diagnosis of human diseases.

ACKNOWLEDGMENTS

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HI13C0040 and HI14C2628). Also, this work was supported by the National Research Foundation of Korea grant funded by the Ministry of Education, Science & Technology (NRF-2010-0028684, NRF-2014-R1A1A1005144) and the Soonchunhyang University Research Fund.

REFERENCES

1. Sabin BR, Peters N, Peters AT. Chapter 20: atopic dermatitis. *Allergy Asthma Proc* 2012;33 Suppl 1:S67-9.
2. Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. *Allergy Asthma Immunol Res* 2016;8:181-90.
3. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. *J Clin Invest* 2004;113:651-7.
4. Pyun BY. Natural history and risk factors of atopic dermatitis in chil-

- dren. *Allergy Asthma Immunol Res* 2015;7:101-5.
5. Bieber T. Atopic dermatitis. *N Engl J Med* 2008;358:1483-94.
 6. Ahn K. The prevalence of atopic dermatitis in Korean children. *Allergy Asthma Immunol Res* 2016;8:1-2.
 7. Lee JH, Han KD, Kim KM, Park YG, Lee JY, Park YM. Prevalence of atopic dermatitis in Korean children based on data from the 2008–2011 Korean National Health and Nutrition Examination Survey. *Allergy Asthma Immunol Res* 2016;8:79-83.
 8. Niebuhr M, Langnickel J, Draing C, Renz H, Kapp A, Werfel T. Dysregulation of toll-like receptor-2 (TLR-2)-induced effects in monocytes from patients with atopic dermatitis: impact of the TLR-2 R753Q polymorphism. *Allergy* 2008;63:728-34.
 9. Wollenberg A, Feichtner K. Atopic dermatitis and skin allergies - update and outlook. *Allergy* 2013;68:1509-19.
 10. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res* 2012;22:850-9.
 11. Breuer K, Wittmann M, Bösch B, Kapp A, Werfel T. Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). *Allergy* 2000;55:551-5.
 12. Chen YE, Tsao H. The skin microbiome: current perspectives and future challenges. *J Am Acad Dermatol* 2013;69:143-55.
 13. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature* 2012;486:207-14.
 14. EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. *Nat Rev Drug Discov* 2013;12:347-57.
 15. Pyun BY. Extracellular vesicle: an unknown environmental factor for causing airway disease. *Allergy Asthma Immunol Res* 2016;8:179-80.
 16. Shin TS, Kim JH, Kim YS, Jeon SG, Zhu Z, Gho YS, et al. Extracellular vesicles are key intercellular mediators in the development of immune dysfunction to allergens in the airways. *Allergy* 2010;65:1256-65.
 17. Hong SW, Kim MR, Lee EY, Kim JH, Kim YS, Jeon SG, et al. Extracellular vesicles derived from *Staphylococcus aureus* induce atopic dermatitis-like skin inflammation. *Allergy* 2011;66:351-9.
 18. Hong SW, Choi EB, Min TK, Kim JH, Kim MH, Jeon SG, et al. An important role of α -hemolysin in extracellular vesicles on the development of atopic dermatitis induced by *Staphylococcus aureus*. *PLoS One* 2014;9:e100499.
 19. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. *Acta Derm Venereol Suppl (Stockh)* 1980;92:44-7.
 20. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. *Dermatology* 1993;186:23-31.
 21. Edgar RC. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* 2010;26:2460-1.
 22. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* 2010;7:335-6.
 23. Drago L, De Grandi R, Altomare G, Pigatto P, Rossi O, Toscano M. Skin microbiota of first cousins affected by psoriasis and atopic dermatitis. *Clin Mol Allergy* 2016;14:2.
 24. Seite S, Flores GE, Henley JB, Martin R, Zelenkova H, Aguilar L, et al. Microbiome of affected and unaffected skin of patients with atopic dermatitis before and after emollient treatment. *J Drugs Dermatol* 2014;13:1365-72.
 25. Choi Y, Park H, Park HS, Kim YK. Extracellular vesicles, a key mediator to link environmental microbiota to airway immunity. *Allergy Asthma Immunol Res* 2017;9:101-6.
 26. Kim JH, Lee J, Park J, Gho YS. Gram-negative and gram-positive bacterial extracellular vesicles. *Semin Cell Dev Biol* 2015;40:97-104.
 27. Campos JH, Soares RP, Ribeiro K, Andrade AC, Batista WL, Torrecilhas AC. Extracellular vesicles: role in inflammatory responses and potential uses in vaccination in cancer and infectious diseases. *J Immunol Res* 2015;2015:832057.